ARTICLE | Company News
Medivation neurology, cancer news
April 5, 2010 7:00 AM UTC
Medivation reduced headcount by 23 (20%) to 88 a month after the company's Dimebon latrepirdine missed the co-primary endpoints in a Phase III trial to treat Alzheimer's disease. As a result, Medivat...